ketanserin and Sclerosis, Systemic

ketanserin has been researched along with Sclerosis, Systemic in 14 studies

Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.

Research

Studies (14)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Baseline Cortical Area Measured by HR-pQCT in SSc Patients With Calcinosis.

Bone cortical area is a bone microarchitecture measurement assessed by High Resolution peripheral Quantitative Computed Tomography (HRpQCT) at the distal tibia. Lower levels of cortical area are associated with more bone fragility. (NCT02663895)
Timeframe: Baseline visit (average approximately 3 hours for the scan)

Baseline Cortical Porosity Measured by HR-pQCT in SSc Patients With Calcinosis.

Bone cortical porosity is a bone microarchitecture measurement assessed by High Resolution peripheral Quantitative Computed Tomography (HRpQCT) at the distal tibia. Higher levels of cortical porosity are associated with more bone fragility. (NCT02663895)
Timeframe: Baseline visit (average approximately 3 hours for the scan)

Change in Cochin Hand Functional Scale

Cochin Hand Functional Scale is a 18-question scale, each question ranges from 0 to 5, with a total score range of 0-90. Higher scores indicates higher disability. (NCT02663895)
Timeframe: Baseline, 12 months

Change in Mawdsley Calcinosis Questionnaire

Mawdsley Calcinosis Questionnaire is an 18-question survey with an overall score of 0-10; each individual question ranges from 0-10, scores are totaled and averaged to and divided by 18 to create the overall score. Higher scores indicate higher disability from calcinosis. (NCT02663895)
Timeframe: Baseline, 12 months

Change in Patient Global Assessment of Calcinosis Severity

Patient global assessment of calcinosis severity at 1 year versus baseline. Score range: 0 to 10 (higher scores indicate more severe calcinosis). (NCT02663895)
Timeframe: Baseline, 12 months

Change in Physician Global Assessment of Calcinosis Severity

Physician global assessment of calcinosis severity at 1 year versus baseline. Score range: 0 to 10 (higher scores indicate more severe calcinosis). (NCT02663895)
Timeframe: Baseline, 12 months

Change in Raynaud Condition Score

The Raynaud Condition Score is a single question questionnaire, ranges from 0-10, where 10 indicates more active Raynaud phenomenon. Raynaud is an exaggerated vascular response to cold exposure or emotion with at least a 2-phase color change in finger(s) and often toe(s) consisting of pallor, cyanosis, and/or reactive hyperemia: usually one phase is pallor. (NCT02663895)
Timeframe: Baseline, 12 months

Median Rate of Change of Calcinosis in Radiograph Following Treatment With Oral Treprostinil as Assessed by a Novel Radiographic Scoring System

"Median rate of change of calcinosis in radiograph following treatment with oral treprostinil as assessed by the Scleroderma Clinical Trial Consortium (SCTC) radiographic scoring system. Historical average SCTC scores in this patient population have ranged from 4.08 to 472.88, with higher scores indicating more severe symptoms.~The SCTC radiographic score for calcinosis is a validated radiographic scoring system to assess the severity of calcinosis affecting the hands of patients with SSc that accounts for area coverage, density, and anatomic location, higher scores mean worse calcinosis. Physician rates density and percentage of area for 22 regions of each hand, each deferentially weighted in the overall score; individual region values are multiplied my their weight then summed to create an overall score." (NCT02663895)
Timeframe: Baseline, month 12

Number of Participants With Treatment-related Adverse Events Following Treatment With Oral Treprostinil

Number of participants with treatment-related adverse events following treatment with oral treprostinil at 12 months. We defined adverse event as any untoward medical experience occurring to a subject during a clinical trial whether or not it is related to the study drug. (NCT02663895)
Timeframe: 12 months

Change in Scleroderma Health Assessment Questionnaire (SHAQ)

"The Scleroderma Health Assessment Questionnaire (SHAQ) has two parts.~The first part is a disability index (DI) that consists of the mean of 8 scores from 8 sections (dressing, arising, eating, walking, hygiene, reach, grip, and activities) ranging from 0 (without any difficulty) to 3 (unable to do), with scores summed and divided by 8. The result is the Health Assessment Questionnaire (HAQ)-DI score, which ranges between 0 and 3.~The second part consists of 6 visual analogue scales (VAS) each ranging from 0 (better outcome) to 10 (worse outcome).~Pain (SHAQ-VAS-Pain)~Intestinal (SHAQ-VAS-GI)~Breathing (SHAQ-VAS-Breathing)~Raynaud (SHAQ-VAS-Raynaud)~Digital ulcers (SHAQ-VAS-DU)~Disease Severity (SHAQ-VAS-Disease Severity)" (NCT02663895)
Timeframe: Baseline, 12 months

Change in Short Form (SF)-36

The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The higher the score the less disability. (NCT02663895)
Timeframe: Baseline, 12 months

Reviews

1 review available for ketanserin and Sclerosis, Systemic

Trials

7 trials available for ketanserin and Sclerosis, Systemic

Other Studies

6 other studies available for ketanserin and Sclerosis, Systemic